The primary objective of this randomized clinical trial is to determine if conventional heart failure pharmacotherapy (ACEI or BB) can prevent trastuzumab-mediated LV remodeling among patients with HER2+ EBC, determined by 12 month change in LV end-diastolic volume (LVEDV) measured using cardiac MRI. This evidence concerns the gene ERBB2 and heart failure.